SRS SYSTEM - Leading the gerd revolution

  • srs-home-6
  • srs-home-5
  • srs-home-4
  • srs-home-2
  • srs-home-3
  • srs-home-7
  • srs-home-1

GERD is caused by abnormal regurgitation of fluids from the stomach into the esophagus.

The SRS™ innovative endoscopy system is for the treatment of Gastroesophageal Reflux Disease (GERD). Medigus’ endoscopic SRS system performs an anterior fundoplication in lieu of current surgical procedures, without opening the abdominal cavity.

The entire SRS system is CE marked and FDA cleared.

READ MORE

PATIENT INFO

A novel system (SRS™) enables a minimally invasive procedure that can provide long lasting relief and improved quality of life for people suffering from acid reflux.
READ MOREpatient info

HEALTHCARE PROFESSIONAL

Medigus' SRS is a cutting edge disposable endoscope that provides you with simple and effective treatment for GERD symptoms in lieu of laparoscopic surgery.
READ MOREdoctor info
Medigus

Medigus is a medical device company specializing in developing innovative endoscopic procedures and devices, including the revolutionary disposable endoscope for the treatment of GERD (Gastroesophageal Reflux Disease).

The company, which was founded in January 2000, is based in Israel and is publicly traded on the TASE. Medigus owns a unique and outstanding technological platform enabling the company to bring into the world state-of-the-art medical device products.

Read more

News

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Prev Next

EAES European Association for Endoscopic Surgery

21-05-2013

June 19-22, 2013
Vienna, Austria
Visit us at booth #25

Read more

Successful Three-Year Follow-Up Data of the SRS™ Pivotal Study in Indiana University Will be Presented at the Digestive Disease Week in Orlando

16-05-2013

Medigus Ltd. (MDGS.TA), a leading medical device company dedicated to the development of innovative endoscopic procedures and technologies, will be presenting the successful three year follow-up da...

Read more

DDW Digestive Disease Week

06-05-2013

May 18-21, 2013
Orlando, Florida

Read more

Successful five-year follow-up data from SRS™ pilot study

05-05-2013

Medigus (TASE:MDGS) announced today that it had received five-year follow-up results of a pilot study of its SRS™ endoscopic system for the treatment of Gastroesophageal Reflux Disease (GERD). The ...

Read more

Medigus Signed a Distribution Agreement in China

12-03-2013

Local distributor to purchase SRS™II systems for a minimum of $3.85 million.

Read more

Medigus completed $8M private placement by OrbiMed

04-03-2013

Medigus (TASE:MDGS) announces that it had closed an $8 million investment by OrbiMed Israel Partners LP. Upon the closing of the investment, Dr. Nissim Darvish, senior managing director at OrbiMed ...

Read more

Columbia Medical Center Offers SRS Procedures

13-02-2013

Medigus (TASE:MDGS) announces that Columbia University Medical Center, Department of Surgery (New-York, New-York), now offers the SRS™ procedure for transoral incisionless treatment of GERD.

Read more

Medigus announces an exclusive distribution agreement for the SRS™II in Turkey

16-01-2013

Medigus (TASE:MDGS) announces an exclusive distribution agreement for the SRS™II in Turkey.

Read more